The use of lecanemab for treating Alzheimer’s disease may help relieve the burden that the disease places on unpaid caregivers, according to a study published Sunday in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. The study collected 345 questionnaires as part of a national survey on Alzheimer’s disease caregivers in China and was carried out in 37 tertiary hospitals across 31 provinces, municipalities and autonomous regions. According to the paper, 51.6% of caregivers reported a basic understanding of AD, with 5.8% demonstrating comprehensive awareness of AD diagnostic criteria. Additionally, 86.7% of the caregivers demonstrated a willingness to continue using lecanemab. Within 6 months, about 68.7% of caregivers noted no significant change in care burden, and 25.8% reported an alleviation of the burden.